In such cases, EGFR-TKIs, gefitinib /erlotinib, are recommended as the first line of treatment for patients with EGFR mutations; however, they do not significantly improve the overall survival, owing to the intrinsic resistance developed during treatment as seen in patients with NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.